Introduction
Tumors displaying microsatellite instability (MSI) either due to germline or epigenetic inactivation of one the mismatch repair (MMR) genes account for approximately 10-15% of colorectal cancers (CRC) (1, 2) . Sporadic MSI tumors have recognizable clinicopathological features such as right-sided location, older age of diagnosis, lower pathological stage and better prognosis (3) (4) (5) . Genetic instability in this subgroup primarily reflects variation in microsatellite tracts due to a defective functioning of the surveillance mechanism performed by the MMR system. This instability is further reflected by more than 30 genes known to have mutations in microsatellite tract repeats, including DNA repair proteins involved in double strand break (DSB) repair through the homologous recombination pathway, such as MRE11 and RAD50 (6) . In particular, a microsatellite tract of 11(T) located at intron 4 of MRE11 is mutated in approximately 80% of MSI tumors and leads to aberrant splicing and a truncated protein (7) . The multiprotein complex integrated by MRE11-RAD50-NBS (MRN complex) is the primary sensor of DSB and recruits other signaling proteins at DSB sites(8). These microsatellite mutations constitute a specific genetic background that can be exploited as potential drug target and predictor of sensitivity to specific therapies focused in DNA damage pathways.
In fact, mutations in MRE11 has been shown to sensitize cells to agents causing replication fork stress as a result of a lack of 3'-5' exonuclease activity, absence of formation of MRE11 foci and ATM autophosphorylation (9) .
Poly(ADP-ribose) polymerase (PARP-1) cooperates with DNA ligases in order to repair single strand breaks whenever the ends need processing (10) . Therefore, inhibitors of Vilar et al (2010) 5 PARP-1 increase the levels of persisting single-strand breaks that will lead to DNA DSB upon replication (11) . DSBs are one of the most important threats to genomic integrity and trigger repair proteins involved in the non-homologous end joining and homologous recombination pathways. Experimental evidence shows a direct interaction between PARP-1 and MRE11 reflected by the fact that PARP-1 is apparently required for rapid accumulation of MRE11 at DSB sites (12) . Therefore, tumor cells harboring mutations of genes involved in homologous recombination such as BRCA1, BRCA2 and MRE11 are particularly vulnerable to DNA damage. Our aim in this study was to assess the activity of the PARP-1 inhibitor ABT-888 in CRC cell lines harboring a mutation in the homologous recombination gene MRE11 that frequently accompany MMR deficiency. Institute Cancer Genome Project web site(13) as detailed in Supplementary Table S1 .
Cell lines were purchased from the American Type Culture Collection (Manassas, VA).
MSI status was also confirmed independently in cell lines, as well as the presence of mutations in the principal oncogenes for CRC. Cells were grown in DMEM/F12 medium supplemented with 10% of fetal bovine serum and 1% penicillin/streptomycin. SW480/SN3 and its derivative SM1.3 expressing a construct for Δ 5-7 MRE11 were generously provided by Dr. Mark Meuth (Institute for Cancer Studies, The University of Sheffield, Sheffield, UK) and has been reported previously (9) . These cell lines were grown in DMEM medium. In addition 46 CRC samples from the Molecular Epidemiology of Colorectal Cancer (MECC)(14) study were assessed for the frequency mutation of MRE11 poly(T)11 in primary colon tumors (Supplementary Table S2 ).
Analysis of MRE11 poly(T)11 and RAD50 poly(A)9 in cell lines and primary tumors.
Analyses for the length of the MRE11 poly(T)11 and RAD50 poly(A)9 were performed on genomic DNA extracted from cell lines and CRC samples microdissected from paraffin embedded tissue blocks. Forward and reverse primers for MRE11 and RAD50 were labeled with FAM. PCRs were performed using GeneAmp Fast PCR Master Mix (Applied Biosystems, Foster City, CA) in separate reactions. The PCR fragments were detected by capillary electrophoresis on ABI370 at the University of Michigan Sequencing Core. The electropherograms were analyzed using GeneMarker v1.51 Expression of MRE11 wild type and mutant transcripts and PARP-1. Total RNA from 10 cell lines was extracted using the TRIzol protocol according to manufacturer's instructions (Invitrogen, Carlsbad, CA). Adequate quantities of high-quality total RNA were determined by Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA).
cDNA was synthesized using High Capacity cDNA Reverse Transcription Kit from 200 ng of RNA. All samples were tested in triplicate. Real-time qPCR was carried out using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) on Applied Biosystems Prism 7900 HT Sequence Detection System. Two sets of primers were designed to assess the independent expression levels of the MRE11 wild type and the mutant transcript, one set for PARP-1 and one for GAPDH that was used as an endogenous control. Primer sequences and PCR conditions are available upon request.
The relative expression of the wild type and mutant transcript of MRE11 and PARP1 was calculated by ∆Ct normalization to the expression of GAPDH.
Immunofluorescence. Cells were cultured on coverslips, fixed, and processed as previously described (15) . For each cell line, Rad51 and γH2AX foci were quantified following fixation of cells 24 hours after being seeded (t=0) and 18 hours after irradiation (7.5 Gy) (t=18). Samples were imaged with an Olympus FV500 confocal microscope (Olympus America) with a 60× objective. For quantification of Rad51 and γH2AX foci, at least 100 cells were visually scored for each condition by two independent observers. Cells with ≥5 foci were scored as positive and percent positivity was compared at baseline and 18 hours following irradiation for three cell lines (SW620, HCT15, and SW48).
Irradiation. Cells were irradiated using a Philips RT250 (Kimtron Medical) at a dose rate of ∼2 Gy/min in the University of Michigan Comprehensive Cancer Center Experimental Irradiation Core.
Statistical analysis of association between expression and mutational status of

MRE11. Comparisons of expression levels between cell lines grouped by MRE11
mutational status across three categories were performed using the rank-based, KruskalWallis ANOVA test followed by posthoc Dunn's test for pairwise differences among groups (MRE11 homozygous versus heterozygous mutants, MRE11 homozygous mutants versus wild-type, MRE11 heterozygous mutants versus wild-type) using SAS version 9.1 (The SAS Institute, Cary, NC). Nonparametric methods were used to protect against violation of normality assumption given the limited sample size. Trizol (Invitrogen, Carlsbad, CA), and total cellular RNA was purified according the instructions of the manufacturer, with additional purification using RNeasy spin columns (Qiagen, Valencia, CA). RNA quality was assessed by 1% agarose gel electrophoresis, and samples were included only if the 18S and 28S bands were discrete and approximately equal. Expression levels were measured in two batches using Affymetrix U133A and U133A Plus 2.0 arrays (Santa Clara, CA). Preparation of target cRNA, hybridization, and scanning were performed according to the protocols of the manufacturer.
Statistical Analysis of Microarray Data. Expression analyses were carried out in the Rsoftware using the package Bioconductor(16). Expression data in both batches were first subjected for quality assessment by creating the density plot of the log-intensity and RNA degradation plot corresponding to each sample. For all 331 samples, MAS 5.0-calculated signal intensities were normalized using the quantile normalization procedure implemented in robust multiarray analysis (17, 18) and the normalized data were log2 transformed. Sample specific median centering and scaling by the standard deviation were additionally applied. Filtering was done to exclude probe sets that were not expressed or probe sets that exhibited low variability across samples. Expression values were required to be above the lower quartile of all expression measurements in at least 25% of samples, and the interquartile range across the samples on log2 scale was required to be at least 0.5. After preprocessing and quality assessment the two batches were aligned. Probes of the U133A array present in the U133A Plus 2.0 were selected and quantile normalized to mimic the distribution of the U133A array. were carried out by two-sample t-test to yield a list of differentially expressed probe sets, discriminating between the two biologic states of interest under consideration. We had information on MSI status available from 300 patients whose characteristics are detailed in Supplementary Table S3 . The issue of multiple testing was addressed by using adjusted P-values after controlling for the overall false discovery rate by Benjamini and Hochberg method (BH-adjusted P-values) (19) . We also evaluated the local false discovery rate associated with our probe selection procedure by using the locfdr package in R (20) . inhibitor Phenanthridinone and others were assessed using the Connectivity Map (21) . We have used five different data sets characterizing MSI-H tumors. Four of them were previously published and retrieved directly from their original publications (22) (23) (24) (25) .
Criteria followed for selection of probe sets and detailed lists have been published previously (26) . The fifth dataset was generated from a total of 300 colorectal fresh frozen tumors collected from the MECC study and analyzed in two batches. (11) tract located in the intron 4 of MRE11. Three had monoallelic and five had biallelic mutations. Only three cell lines harbored mutations in an exonic polyA(9) repeat of RAD50 (Table 1 and Supplementary Table S1 ), and all of them were MSI. Therefore we decided to focus our attention on MRE11. To confirm the frequency of the MRE11-intron 4 mutation we genotyped 46 tumors from the MECC study (Supplementary Table S2 ). CAN-10-1120 addition, we assessed the basal levels of PARP-1 expression and no differences were observed between MRE11 mutant and wild-type cell lines ( Figure 1D ).
MSI-H tumors present with changes in gene expression related to the homologous recombination pathway. Once we observed that deficiency in MRE11 exists among MSI tumors, our interest was focused on assessing if the homologous recombination pathway showed evidence of deregulation in MSI tumors. Therefore we examined the expression levels of those genes integrated in the KEGG pathway hsa03440 using data from a total of 300 CRCs from the MECC study (Supplementary Table S3 ). As shown in Figure 2A and Supplementary Table S6 Table 2 ) were very similar across signatures. 1,5-Isoquinolinediol was correlated in only one of the data sets. However, based on previous in vitro studies this compound is the least specific in terms of PARP inhibition of the three compounds studied.
Low levels of MRE11 wild type transcripts increase the sensitivity to the PARP-1 inhibitor ABT-888 in MSI-H cell lines.
We selected ABT-888 to assess the effects of a novel PARP-1 inhibitor in a colorectal cancer model deficient in MRE11. We used three wild-type, one monoallelic and four biallelic mutants of MRE11 cell lines for these experiments. Since the monoallelic mutant cell line has intermediate expression levels of the MRE11 mutant transcript but closer to wild-type cells we decided to group it along with them for IC50 and cytotoxicity at 10 μM comparisons. A significant difference in cytotoxicity was found at 10 μM concentration between biallelic mutants and wild-type plus monoallelic mutants (44.5% versus 80.65%, P-value=0.028, Figure 4A ) and a 2.5-fold difference in terms of IC50 when compared between these two groups (8.9 versus 22.23 μM, P-value=0.028, Figure 4B ). Then we studied the correlation between levels of expression of the mutant transcript of MRE11 and cytotoxicity to ABT-888 at a concentration of 10 μM showing a significant association between both (R=-0.9048, Pvalue=0.0046, Figure 4C ). Cell cycle changes revealed an arrest in G1 and a decrease in S-phase after treatment with ABT-888 in MRE11 biallelic mutants ( Figure 4D Finally we conducted experiments using two different approaches to diminish the expression of MRE11. First, shRNA was used to knock down the expression of MRE11 in a wild type MRE11 and MSS cell line to further assess its role as a mediator of the effect of PARP-1 inhibition. As depicted in Figure 5A we were able to achieve a significant, but incomplete, knockdown of MRE11 gene expression in the SW-480 cell line. We observed differences in proliferation between mock shRNA and MRE11 shRNA stable transfectants when 50 µM of ABT-888 was used, pointing towards a potential role of MRE11 as responsible for the drug effects (Fig 5B) . Therefore, a second validation experiment using the cell line SW480/SN3 and its derivative SM1.3 was performed. 
Discussion
Genetic instability in MSI tumors is secondary to the presence of a deficiency in the MMR system that introduces a myriad of mutations in downstream genes (27) . One of these gene targets is MRE11, a gene that is implicated in homologous recombination.
MRE11 forms a multiprotein complex with RAD50 and NBS1 that signals double strand DNA breaks and then recruits other proteins that initiate DNA repairing. We have observed frequent mutations in an specific poly(T)11 tract located in the intron 4 of MRE11 in MSI colorectal tumors that is consistent with previous reports (28, 29) , thus confirming that MSI is strongly associated with this MRE11 mutation.
At the present time deficiency in homologous recombination has been therapeutically exploited therapeutically in those tumors exhibiting mutations in BRCA1 and BRCA2 (30) .
This novel therapeutic approach is based on the fact that simultaneous deficiency in two genes may introduce lethality in a biologic system that otherwise would be tolerant to the loss of one of them (31) . Although the role of BRCA1 and BRCA2 is more predominant in homologous recombination than MRE11, our hypothesis is that other components of this pathway may also predict an increase in the sensitivity to PARP-1 inhibitors. In terms of the biology of double strand break repair, we have shown that cell lines harboring transfected with a shRNA that achieved a level of down-regulation only 25%. Despite this limited suppression, we observed a higher sensitivity to PARP-1 inhibitors at 50 µM of ABT-888 following this level of decreased MRE11 expression. In addition, we performed a second set of validation studies using a cell line model transfected with a transcript that contains a mutation in MRE11 lacking exons 5-7 and leads to dramatically lower levels of the wt MRE11 at 80% of the baseline compared to the parental cell line.
Again we observed that PARP inhibition exerted a higher effect on the derivative cell line SM1.3 at a lower concentration of the drug of 10 µM but not at 50 µM. Therefore, these data are not entirely consistent with dose-response inhibition across all concentrations, and suggest that either inhibitory thresholds might not be perfectly modeled by our CAN-10-1120 transfection system, or that other genetic variation may contribute to PARP sensitivity. In fact, we have been able to identify by using gene expression profiling other candidate genes that are involved in the homologous recombination pathway and significantly deregulated in MSI-H tumors.
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